Wijnhoven Abstract Esophagectomy is considered the cornerstone of the radical treatment of esophageal cancer.

Most (n=12) of the trials were conducted in the non-small-cell lung cancer setting, followed by four in melanoma and three each in small-cell lung cancer, renal cell carcinoma, and urothelial cancer, while other tumor types such as gastroesophageal and breast cancer were represented in one or two trials.

Adding tiragolumab to atezolizumab plus carboplatin and etoposide provides no additional progression-free or overall survival benefit to patients with untreated extensive-stage small-cell lung cancer, phase 3 study data show.

Esophageal-sparing intensity-modulated radiotherapy reduces the incidence of esophagitis but not does not improve esophageal quality of life versus standard palliative thoracic radiotherapy in people with advanced lung cancer, research shows.

Electronic patient-reported outcomes to monitor immune-related adverse events during immunotherapy for cancer is associated with a reduction in the incidence of serious adverse events, emergency department visits, and treatment discontinuations, and a better quality of life, research suggests.

The positive opinion in this setting adds to the recommended use of pembrolizumab in patients with melanoma, non-small-cell lung cancer, classical Hodgkin lymphoma, urothelial cancer, head and neck squamous cell carcinoma, renal cell carcinoma, esophageal or gastroesophageal junction adenocarcinoma, and cancer of the colon or rectum. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

The number of new cancer diagnoses during the first year of the COVID-19 pandemic was lower than in the prepandemic period, report US researchers.

In particular, response rates were better with high versus low TMB in the NSCLC, melanoma, sarcoma, bladder cancer, head and neck cancer, SCLC, colorectal cancer, endometrial cancer, esophageal cancer, ovarian cancer, and breast cancer cohorts.

By contrast, there were a 64.2%, 41.2%, and 36.3% increases in radiotherapy courses for bladder, esophageal, and rectal cancer, respectively, in April 2020, compared with April 2019.

The PD-1 inhibitor pembrolizumab elicits durable responses and has a manageable adverse event profile in previously treated patients with advanced gastric or gastroesophageal junction adenocarcinoma, indicates the KEYNOTE-059 trial.

Using the US National Cancer Database, Porembka and team identified 10,086 adults (mean age 61 years, 88% men) with clinical stage T1N1-3M0 or T2-4N0-3M0 adenocarcinoma of the distal esophagus or gastric cardia who were treated with preoperative chemoradiotherapy and curative-intent resection.

UK researchers have called for urgent action to be taken to avoid unnecessary cancer deaths as a result of delayed surgery due to the COVID-19 pandemic.

An analysis of cancer patients with comorbid COVID-19 in Wuhan, China, has identified factors associated with an increased risk for a more severe clinical course.

The decline in diagnoses was significant for each of the tumor types, with mean weekly reductions ranging from 24.7% for pancreatic cancer to 51.8% for breast cancer.